Analysis: Zhengda Tianqing ~ innovative drug R & D pipeline

Inscription Zhengda Tianqing Pharmaceutical Group, an innovative pharmaceutical group enterprise integrating scientific research, production and sales, is a well-known domestic research and development and production base of liver health drugs, a key high-tech enterprise of the state and a key backbone enterprise of Lianyungang new pharmaceutical industry base of the national torch plan Meanwhile, Zhengda Tianqing always takes scientific and technological innovation as an important strategy of enterprise development, which is a domestic one One of the pharmaceutical companies with more investment in innovative drug research has invested more than 1 billion yuan / year in R & D, which is gradually catching up with multinational companies, and has gained a lot The huge investment of R & D cost in the overall overview of innovative drug pipeline makes Zhengda Tianqing have a sustained momentum While improving the superior products, the innovative drug pipeline has begun to take shape, not only there are many drugs in clinical research, but also the listed drugs are praised by the industry By the time of publication, Zhengda Tianqing had independently developed 2 class 1 new drugs on the market; 21 drugs under clinical research and 9 clinical application varieties; the treatment fields mainly covered tumors, infectious diseases, etc 2 innovative drugs on the market As a well-known R & D and production base of liver health drugs in China, Zhengda Tianqing has one of the few innovative listed drugs in China, magnesium isoglycolate, which was used in the clinical treatment of acute drug-induced liver injury / chronic viral hepatitis, and was listed in 2005 In addition, the recently listed androtinib, which is praised by the whole domestic pharmaceutical industry, is used in the treatment of non-small At the same time, many related indications are in progress Enrotinib hydrochloride Androtinib hydrochloride, developed by Zhengda Tianqing, is a new type of small molecule multi-target tyrosine kinase inhibitor, which can effectively inhibit VEGFR, PDGFR, FGFR, c-kit and other kinases, and has the effect of anti-tumor angiogenesis and tumor growth inhibition; it was approved by CFDA in May 2018 and listed on the market under the trade name of fukewei ®, which is used for the treatment of advanced non-small cell lung cancer; at the same time, other clinical applications The indications are also in the process See Table 2 for details Synthesis route: magnesium isoglycolate Magnesium isoglycyrrhizate is a kind of liver cell protective agent, which has the functions of anti-inflammatory, protecting liver cell membrane and improving liver function It is used to treat chronic viral hepatitis and acute drug-induced liver injury and improve liver dysfunction It was first approved to be listed by China food and Drug Administration (CFDA) on October 9, 2005, and was listed and sold by Zhengda Tianqing Pharmaceutical Co., Ltd in China The recommended dose is 0.1 mg or 0.2 mg per time for chronic viral hepatitis, once a day, once every 4 weeks for a course; for acute liver dysfunction, the recommended dose is 0.1 mg per time, once a day, once every 2 weeks for a course Synthesis route: interestingly, under the current condition, most of the research and development status of Zhengda Tianqing clinical research and development varieties are in phase 1 clinical, and the indications are mainly tumor and hepatitis See Table 5 for details Compared with other large pharmaceutical enterprises, Zhengda Tianqing currently has more candidate drugs in clinical application status, and most of the information is not disclosed See Table 6 for details feel The author's biggest feeling about "Zhengda Tianqing" is that it is steady, making money and moving like a dragon.. In recent years, with its steady drive and dedication to the product line, Zhengda Tianqing has formed a series of products, many of which have a very high market share At the same time, at the technical level, it is also constantly moving forward to improve itself; style Different from other large pharmaceutical companies around the region and the first echelon in China, they are really making drugs in a down-to-earth way It's not hard to see their future direction by further observing their product R & D pipeline I hope that the future of Tianqing will be as clear as her name, and at the same time, it will bring a bright future for patients! (it's really not a soft article...) reference: Official Website of drug data and Drug Administration Tianqing official website